Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Neutral

B

Apogee Therapeutics, Inc. Common Stock (APGE)

Biological Products, (no Disgnostic Substances)

https://www.apogeetherapeutics.com

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.

221 CRESCENT ST., BUILDING 17, SUITE 102B
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/14/2023

Market Cap

2,624,967,937

Shares Outstanding

37,190,000

Weighted SO

48,017,621

Total Employees

N/A

Upcoming Earnings

08/26/2024

Similar Tickers

Beta

2.3248

Last Div

0.0000

Range

14.19-72.29

Chg

-0.3950

Avg Vol

457087

Mkt Cap

2624967937

Exch

NASDAQ

Country

US

Phone

650-394-5230

DCF Diff

42.5145

DCF

2.2955

Div Yield

0.0000

P/S

0.0000

EV Multiple

-16.5564

P/FV

3.2803

Div Yield %

0.0000

P/E

-21.4188

PEG

0.1945

Payout

0.0000

Current Ratio

27.6985

Quick Ratio

27.6985

Cash Ratio

12.4832

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

31036.2308

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0291

ROA

-0.1480

ROE

-0.1929

ROCE

-0.1853

NI/EBT

1.0000

EBT/EBIT

0.8242

EBIT/Rev

0.0000

Debt Ratio

0.0051

D/E

0.0053

LT Debt/Cap

0.0031

Total Debt/Cap

0.0052

Int Coverage

0.0000

CF/Debt

-27.0806

Equity Multi

1.0349

Rec Turnover

0.0000

Pay Turnover

0.0118

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-1.9565

FCF/Share

-1.9665

Cash/Share

11.9655

OCF/Sales

0.0000

FCF/OCF

1.0051

CF Coverage

-27.0806

ST Coverage

-65.7372

CapEx Coverage

-194.3234

Div&CapEx Cov

-194.3234

P/BV

3.2803

P/B

3.2803

P/S

0.0000

P/E

-21.4188

P/FCF

-23.6188

P/OCF

-22.9520

P/CF

-22.9520

PEG

0.1945

P/S

0.0000

EV Multiple

-16.5564

P/FV

3.2803

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 06, 22:00 Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 Investing.com Jul 06, 04:19 Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) By GuruFocus - Investing.com Canada Investing.com Jul 06, 02:57 Apogee Therapeutics CEO sells shares worth over $558k By Investing.com - Investing.com Australia Investing.com Jul 06, 02:56 Apogee Therapeutics CMO sells over $225k in company stock By Investing.com - Investing.com Australia GlobeNewswire Inc. Jan 02, 07:30 Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky GlobeNewswire Inc. Nov 13, 07:30 Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Revenue Product Segmentation